Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Proteostasis Therapeutics Inc    PTI

PROTEOSTASIS THERAPEUTICS INC

(PTI)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
3.91(c) 3.75(c) 3.93(c) 4.14(c) 4.07(c) Last
8 425 132 2 551 877 1 079 028 1 575 038 721 276 Volume
+21.81% -4.09% +4.80% +5.34% -1.69% Change
More quotes
Financials (USD)
Sales 2018 3,95 M
EBIT 2018 -65,4 M
Net income 2018 -63,5 M
Finance 2018 103 M
Yield 2018 -
Sales 2019 4,06 M
EBIT 2019 -93,9 M
Net income 2019 -93,1 M
Finance 2019 29,3 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 24,5x
EV / Sales2019 42,0x
Capitalization 200 M
More Financials
Company
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has... 
Sector
Biotechnology & Medical Research
Calendar
02/27 | 01:00pmPresentation
More about the company
Surperformance© ratings of Proteostasis Therapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTEOSTASIS THERAPEUTICS
02/11PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (for..
AQ
02/11Proteostasis Therapeutics Up 25%; BlackRock Disclosed 5.9% Stake Friday
DJ
02/06PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (for..
AQ
02/06PROTEOSTASIS THERAPEUTICS : Appoints Emmanuel Dulac and Kim Drapkin to Board of ..
PR
01/07PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Reg..
AQ
2018PROTEOSTASIS THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2018PROTEOSTASIS THERAPEUTICS : Provides Clinical Enrollment Update
PR
2018Proteostasis in Licensing Pact With Roche's Genentech
DJ
2018PROTEOSTASIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Re..
AQ
2018PROTEOSTASIS THERAPEUTICS : Announces Global License Agreement with Genentech
PR
More news
Sector news : Bio Therapeutic Drugs
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Bio Therapeutic Drugs
Chart PROTEOSTASIS THERAPEUTICS INC
Duration : Period :
Proteostasis Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTEOSTASIS THERAPEUTICS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 13,8 $
Spread / Average Target 239%
EPS Revisions
Managers
NameTitle
Meenu Chhabra Karson President, Chief Executive Officer & Director
Michael James Barrett Chairman
Marija Zecevic Chief Operating Officer
Helen M. Boudreau Treasurer, Chief Financial & Accounting Officer
Po-Shun Lee Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOSTASIS THERAPEUTICS INC25.62%200
GILEAD SCIENCES6.11%87 436
VERTEX PHARMACEUTICALS12.08%48 081
REGENERON PHARMACEUTICALS9.37%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252